Policy & Regulation
GSK secures first global approval for Hibsago in Japan
24 August 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that it has received Japan's first global approval for Hibsago (bepirovirsen) as a functional cure fo...
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
24 August 2026 - South Korean pharmaceutical company Hanmi Pharm Co Ltd announced on Monday that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group (SIX: ...
Rznomics joins Lilly Gateway Labs to accelerate RNA therapeutics
24 August 2026 - Rznomics Inc (KOSDAQ:476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, announced on Sunday that it is joining Lilly G...
Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types
24 August 2026 - Anbogen Therapeutics Inc (TPEx:7784), a Taiwan-based, clinical-stage precision oncology company, announced on Sunday that it has entered into a Collaborative Research Agreement (CRA) ...
CureGene commences dosing in Phase I trial of CG-0416
24 August 2026 - Chinese pharmaceutical company CureGene announced on Friday that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-beta agoni...
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
21 August 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Friday that it has completed the acquisition of Kartos Therapeutics, adding the clinical-stage bio...